Profile data is unavailable for this security.
About the company
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder.
- Revenue in USD (TTM)232.00k
- Net income in USD-152.39m
- Incorporated2020
- Employees119.00
- LocationATAI Life Sciences NVWallstrasse 16Berlin 10179GermanyDEU
- Phone+49 8 921539035
- Fax+49 89 215390351
- Websitehttps://atai.life/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MeiraGTx Holdings PLC | 15.92m | -129.62m | 255.98m | 343.00 | -- | 2.17 | -- | 16.08 | -2.87 | -2.87 | 0.3557 | 2.43 | 0.0499 | -- | 0.7283 | 46,414.00 | -40.61 | -31.71 | -53.10 | -39.00 | -- | -- | -814.16 | -490.79 | -- | -8.65 | 0.3763 | -- | -57.77 | -- | -62.91 | -- | 33.67 | -- |
| Immuneering Corp | 316.96k | -50.51m | 256.96m | 73.00 | -- | 2.34 | -- | 810.70 | -1.91 | -1.91 | 0.012 | 4.16 | 0.0022 | -- | 2.45 | 4,341.92 | -34.95 | -- | -36.69 | -- | 50.11 | -- | -15,936.89 | -- | -- | -- | 0.00 | -- | -84.76 | -- | -50.63 | -- | -- | -- |
| Precigen Inc | 26.91m | -79.78m | 257.24m | 209.00 | -- | 1.68 | -- | 9.56 | -0.3979 | 0.1408 | 0.1342 | 0.6066 | 0.0935 | 20.68 | 22.50 | 128,751.20 | -27.71 | -35.54 | -34.49 | -41.95 | 76.44 | 50.38 | -296.47 | -218.81 | 1.50 | -12.91 | 0.255 | -- | 88.61 | -34.28 | 28.00 | -- | -39.53 | -- |
| Thorne HealthTech Inc | 219.02m | 6.40m | 258.39m | 496.00 | 40.23 | 1.98 | 25.67 | 1.18 | 0.1216 | 0.1216 | 4.16 | 2.46 | 1.14 | 2.10 | 22.27 | 441,568.40 | 2.29 | -- | 2.86 | -- | 52.66 | -- | 2.01 | -- | 1.33 | 43.15 | 0.0266 | -- | 33.80 | -- | 211.55 | -- | -- | -- |
| Adicet Bio Inc | 24.99m | -69.79m | 259.88m | 132.00 | -- | 0.889 | -- | 10.40 | -1.69 | -1.69 | 0.5868 | 6.81 | 0.0746 | -- | 270.16 | 189,318.20 | -20.84 | -32.92 | -22.03 | -35.87 | -- | -- | -279.28 | -548.85 | -- | -- | 0.00 | -- | 156.83 | -- | -12.57 | -- | 228.31 | -- |
| Rani Therapeutics Holdings Inc | 0.00 | -30.59m | 259.91m | 163.00 | -- | 7.05 | -- | -- | -0.6201 | -0.6201 | 0.00 | 0.7459 | 0.00 | -- | -- | 0.00 | -54.55 | -- | -111.65 | -- | -- | -- | -- | -- | -- | -- | 0.2826 | -- | -100.00 | -- | -267.16 | -- | -- | -- |
| ATAI Life Sciences NV | 232.00k | -152.39m | 263.96m | 119.00 | -- | 1.01 | -- | 1,137.74 | -0.9779 | -0.9779 | 0.0015 | 1.57 | 0.0006 | -- | 0.028 | 1,949.58 | -39.30 | -- | -42.55 | -- | -- | -- | -60,953.02 | -- | -- | -- | 0.0538 | -- | -98.86 | -- | 9.19 | -- | -- | -- |
| Pharvaris NV | 0.00 | -53.65m | 265.06m | 34.00 | -- | 1.32 | -- | -- | -1.80 | -1.80 | 0.00 | 5.94 | 0.00 | -- | -- | 0.00 | -23.22 | -- | -24.69 | -- | -- | -- | -- | -- | -- | -- | 0.0011 | -- | -- | -- | -64.44 | -- | -- | -- |
| Acrivon Therapeutics Inc | -100.00bn | -100.00bn | 265.45m | 39.00 | -- | -- | -- | -- | -- | -- | -- | 2.42 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -206.13 | -- | -- | -- |
| P3 Health Partners Inc | 969.12m | -254.88m | 265.53m | 500.00 | -- | 3.39 | -- | 0.274 | -6.13 | -6.13 | 23.31 | 0.3212 | 1.33 | -- | 15.05 | 1,938,240.00 | -157.06 | -- | -1,366.05 | -- | -1.96 | -- | -118.44 | -- | -- | -49.12 | 0.0707 | -- | 31.27 | -- | -280.97 | -- | -- | -- |
| Organogenesis Holdings Inc | 450.89m | 15.53m | 266.29m | 1.03k | 17.31 | 1.00 | 10.14 | 0.5906 | 0.1173 | 0.1173 | 3.43 | 2.03 | 1.01 | 4.22 | 5.25 | 437,760.20 | 3.48 | 1.61 | 4.22 | 2.03 | 76.71 | 73.63 | 3.44 | 1.41 | 2.64 | 12.23 | 0.2104 | 0.00 | -3.67 | -- | -83.63 | -- | -- | -- |
| Outlook Therapeutics Inc | 0.00 | -70.25m | 269.50m | 17.00 | -- | 17.10 | -- | -- | -0.3165 | -0.3165 | 0.00 | 0.0614 | 0.00 | -- | -- | 0.00 | -99.39 | -205.52 | -132.13 | -2,965.91 | -- | -- | -- | -1,950.13 | -- | -18.29 | 0.6689 | -- | -- | -- | -24.24 | -- | -- | -- |
| PepGen Inc | 0.00 | -69.10m | 270.35m | 45.00 | -- | 1.51 | -- | -- | -3.01 | -3.01 | 0.00 | 7.58 | 0.00 | -- | -- | 0.00 | -38.28 | -- | -41.64 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -153.30 | -- | -- | -- |
| Codexis, Inc. | 138.59m | -33.59m | 270.38m | 248.00 | -- | 1.86 | -- | 1.95 | -0.5138 | -0.5138 | 2.12 | 2.20 | 0.558 | 23.85 | 3.53 | 558,834.70 | -13.52 | -11.99 | -16.21 | -14.13 | 72.56 | 76.84 | -24.24 | -23.04 | 3.28 | -- | 0.00 | -- | 32.30 | 22.61 | -57.86 | -- | 53.18 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -115.91m | 270.86m | 70.00 | -- | 0.4226 | -- | -- | -1.39 | -1.39 | 0.00 | 7.69 | 0.00 | -- | -- | 0.00 | -16.10 | -- | -16.99 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -195.64 | -- | -- | -- |
Data as of Mar 30 2023. Currency figures normalised to ATAI Life Sciences NV's reporting currency: US Dollar USD
10.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 31 Dec 2022 | 5.66m | 3.41% |
| Suvretta Capital Management LLCas of 31 Dec 2022 | 1.64m | 0.99% |
| Morgan Stanley Investment Management, Inc.as of 31 Dec 2022 | 1.58m | 0.95% |
| BlackRock Fund Advisorsas of 31 Dec 2022 | 1.43m | 0.86% |
| Cerity Partners LLCas of 31 Dec 2022 | 1.34m | 0.81% |
| Rubric Capital Management LPas of 31 Dec 2022 | 1.32m | 0.80% |
| Millennium Management LLCas of 31 Dec 2022 | 1.24m | 0.75% |
| Two Sigma Investments LPas of 31 Dec 2022 | 974.59k | 0.59% |
| Morgan Stanley & Co. LLCas of 31 Dec 2022 | 797.38k | 0.48% |
| Medical Strategy GmbHas of 30 Nov 2022 | 747.80k | 0.45% |
More ▼
Data from 30 Nov 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
